Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone
Status:
Not yet recruiting
Trial end date:
2024-05-15
Target enrollment:
Participant gender:
Summary
The last decade has shown a progressive scientific interest for new strategies to improve the
outcomes of controlled ovarian stimulation (COS).
Given the fact that interovulatory period has been described to have multiple waves of
follicular recruitment, luteal phase ovarian stimulation (LPOS) has been proposed as new
protocol for COS, with satisfactory ovarian response and pregnancy outcomes. On the other
hand progestin-primed ovarian stimulation (PPOS) is today considered an innovative protocol
aiming to achieve multi-follicle recruitment and block the luteinizing hormone (LH) surge
through progesterone administration in place of the traditional down regulating or
gonadotropin-releasing hormone (GnRH) antagonist. This protocol has been shown to be equally
effective as LH suppression with GnRH antagonist reporting equivalent oocyte retrieval rates,
endocrine profiles, viable embryo numbers, and pregnancy outcomes. Due to the feasibility and
patients-friendly characteristics of PPOS in oocytes donors, the current study aims to
investigate the impact on the number of cumulus-oocyte complexes (COCs) when a PPOS protocol
is associated to both conventional follicular phase stimulation and LPOS for vitrification of
oocytes in oocyte donors. Moreover, it aims to determine whether LPOS using PPOS protocol has
comparable outcomes to conventional follicular phase stimulation with PPOS protocol, in
oocyte donor patients.